Pleuropulmonary and Bronchial Infections

Investigational RSV Vaccine Gets Fast Track Status

Diana Ernst, RPh
|
Smoking cannabis may increase the risk of respiratory disease such as chronic bronchitis, but quitting is likely to reduce the symptoms. It is unknown at this time whether cannabis use is linked to the development of COPD or asthma.
Smoking cannabis may increase the risk of respiratory disease such as chronic bronchitis, but quitting is likely to reduce the symptoms. It is unknown at this time whether cannabis use is linked to the development of COPD or asthma.
An investigational vaccine to protect against respiratory syncytial virus infection has received Fast Track designation from the FDA.

An investigational vaccine to protect against respiratory syncytial virus (RSV) infection has received Fast Track designation from the Food and Drug Administration (FDA).

MV-012-968, a live attenuated vaccine, is being developed by Meissa Vaccines. The Company is currently recruiting healthy adults for a phase 1 trial that will assess the tolerability and immunogenicity of the RSV vaccine.

RSV is a common respiratory virus that generally results in mild, cold-like symptoms. However for certain patients, particularly children and older adults, RSV infection can lead to significant complications such as bronchiolitis and pneumonia.

Related Articles

“A safe and effective RSV vaccine is a significant global health priority, and if we are successful, we can save thousands of lives and help millions of patients around the world,” said Martin Moore, PhD, cofounder and CEO of Meissa. “Fast Track Designation of MV-012-968 accelerates our ability to develop a much-needed RSV vaccine.”

For more information visit meissavaccines.com.

Related Content

This article originally appeared on MPR

  • Latest News Your top articles for Monday

  • Haymarket Medical NetworkTop Picks

  • Loading...

    Continuing Medical Education (CME/CE) Courses

    Show More